Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate

PURPOSE: The objective of this study was to assess the treatment for patients with rheumatoid arthritis (RA) in the USA. PATIENTS AND METHODS: This study entailed analysis of claims data for patients with RA who initiated treatment with oral methotrexate (MTX) or a biologic in 2009 (n=48,910) or 201...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Dell, James R, Cohen, Stanley B, Thorne, J Carter, Kremer, Joel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037273/
https://www.ncbi.nlm.nih.gov/pubmed/30013407
http://dx.doi.org/10.2147/OARRR.S169152
_version_ 1783338305024163840
author O’Dell, James R
Cohen, Stanley B
Thorne, J Carter
Kremer, Joel
author_facet O’Dell, James R
Cohen, Stanley B
Thorne, J Carter
Kremer, Joel
author_sort O’Dell, James R
collection PubMed
description PURPOSE: The objective of this study was to assess the treatment for patients with rheumatoid arthritis (RA) in the USA. PATIENTS AND METHODS: This study entailed analysis of claims data for patients with RA who initiated treatment with oral methotrexate (MTX) or a biologic in 2009 (n=48,910) or 2012 (n=107,636) and had follow-up for 4 years (2009 cohort) or 2 years (2012 cohort). RESULTS: A biologic was initiated before MTX for 27% of the 2009 cohort and 36% of the 2012 cohort. Concomitant use of MTX and a biologic declined from 74.1% (2009 cohort) to 45.4% (2012 cohort). CONCLUSION: MTX is underused in the treatment of RA in the USA.
format Online
Article
Text
id pubmed-6037273
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-60372732018-07-16 Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate O’Dell, James R Cohen, Stanley B Thorne, J Carter Kremer, Joel Open Access Rheumatol Original Research PURPOSE: The objective of this study was to assess the treatment for patients with rheumatoid arthritis (RA) in the USA. PATIENTS AND METHODS: This study entailed analysis of claims data for patients with RA who initiated treatment with oral methotrexate (MTX) or a biologic in 2009 (n=48,910) or 2012 (n=107,636) and had follow-up for 4 years (2009 cohort) or 2 years (2012 cohort). RESULTS: A biologic was initiated before MTX for 27% of the 2009 cohort and 36% of the 2012 cohort. Concomitant use of MTX and a biologic declined from 74.1% (2009 cohort) to 45.4% (2012 cohort). CONCLUSION: MTX is underused in the treatment of RA in the USA. Dove Medical Press 2018-07-03 /pmc/articles/PMC6037273/ /pubmed/30013407 http://dx.doi.org/10.2147/OARRR.S169152 Text en © 2018 O’Dell et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
O’Dell, James R
Cohen, Stanley B
Thorne, J Carter
Kremer, Joel
Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate
title Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate
title_full Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate
title_fullStr Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate
title_full_unstemmed Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate
title_short Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate
title_sort treatment of rheumatoid arthritis in the usa: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037273/
https://www.ncbi.nlm.nih.gov/pubmed/30013407
http://dx.doi.org/10.2147/OARRR.S169152
work_keys_str_mv AT odelljamesr treatmentofrheumatoidarthritisintheusaprematureuseoftumornecrosisfactorinhibitionandunderutilizationofconcomitantmethotrexate
AT cohenstanleyb treatmentofrheumatoidarthritisintheusaprematureuseoftumornecrosisfactorinhibitionandunderutilizationofconcomitantmethotrexate
AT thornejcarter treatmentofrheumatoidarthritisintheusaprematureuseoftumornecrosisfactorinhibitionandunderutilizationofconcomitantmethotrexate
AT kremerjoel treatmentofrheumatoidarthritisintheusaprematureuseoftumornecrosisfactorinhibitionandunderutilizationofconcomitantmethotrexate

Ejemplares similares